ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1117

Ocular Scleral Pathology: Clinical Features and Systemic Treatment in 175 Patients from a Single University Center

Lara Sánchez-Bilbao1, Vanesa Calvo-Río2, José Luis Martin-Varillas3, Carmen Álvarez-Reguera1, Alba Herrero-Morant1, Iñigo Gonzalez-Mazon4, Rosalia Demetrio-Pablo1, Miguel Ángel gonzalez-Gay5 and Ricardo Blanco2, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Hospital Sierrallana, Torrelavega, Spain, 4H. U. Marques de Valdecilla, Santander, Spain, 5Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Meeting: ACR Convergence 2021

Keywords: autoimmune diseases, Episcleritis, Scleritis, spondyloarthritis, Systemic treatmen

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 8, 2021

Session Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Ocular scleral pathology (OSP) includes episcleritis and scleritis. Episcleritis is generally a benign disease with a self-limited course, while scleritis is a more severe ocular condition. In some severe and refractory cases systemic therapy may be required.

In a wide series with OSP our aim was to assess a) underlying diseases and b) systemic treatment.

Methods: Study of unselected all consecutive patients studied in a single University Hospital during the last ten years with: a) episcleritis and b) scleritis diagnosed by clinical features and slit-lamp (Watson and Hayreh criteria). Best corrected visual acuity (BCVA) and intraocular pressure (IOP) were measured at diagnosis and after systemic treatment.

Results: We studied 175 patients (106 women/ 69 men) /212 affected eyes with OSP (episcleritis=135; scleritis=40); mean age 48.9±14.2 years.

OSP was unilateral in 138 (78.9%), recurrent in 74 (42.9%) and chronic in 21 (12%). Most of them were idiopathic (n=81, 46.3%) while associated with IMID were 43.4% (TABLE). The most important underlying IMID were spondyloarthritis and inflammatory bowel disease, without significant differences between scleritis and episcleritis. Granulomatosis with polyangiits and systemic lupus erythematosus were more frequent in scleritis, not reaching statistical significance.

Regarding treatment, topical treatment was used in all patients. 41.1% received systemic treatment, including systemic glucocorticoids, cDMARDS and bDMARDs. Systemic glucocorticoids and Methotrexate were used more frequently in scleritis (TABLE). The main indication for biologic therapy was related to underlying IMID in both groups, but 7 bDMARDs in scleritis were indicated for systemic and ocular compromise.

BVCA and IOP improved significantly after systemic treatment in scleritis (FIGURE).

Conclusion: OSP is a relatively frequent entity. It is necessary to exclude an underlying systemic disease to establish correct systemic treatment.


Disclosures: L. Sánchez-Bilbao, None; V. Calvo-Río, None; J. Martin-Varillas, None; C. Álvarez-Reguera, None; A. Herrero-Morant, None; I. Gonzalez-Mazon, None; R. Demetrio-Pablo, None; M. gonzalez-Gay, None; R. Blanco, Brystol Myers Squibb, 6.

To cite this abstract in AMA style:

Sánchez-Bilbao L, Calvo-Río V, Martin-Varillas J, Álvarez-Reguera C, Herrero-Morant A, Gonzalez-Mazon I, Demetrio-Pablo R, gonzalez-Gay M, Blanco R. Ocular Scleral Pathology: Clinical Features and Systemic Treatment in 175 Patients from a Single University Center [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/ocular-scleral-pathology-clinical-features-and-systemic-treatment-in-175-patients-from-a-single-university-center/. Accessed February 4, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ocular-scleral-pathology-clinical-features-and-systemic-treatment-in-175-patients-from-a-single-university-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences